Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01896388
Other study ID # G25013
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date January 21, 2014
Est. completion date March 2019

Study information

Verified date March 2019
Source Chiba University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Accumulating evidence suggests a key role of the N-methyl-D-aspartate (NMDA) receptor in the pathophysiology of post-traumatic stress disorder (PTSD). Recent studies suggest that the NMDA receptor antagonist ifenprodil tartrate may be a potential therapeutic drug for PTSD. The purpose of this study is to confirm whether ifenprodil tartrate is effective in the treatment of adolescents PTSD patients. If ifenprodil tartrate is effective in these patients, this study contributes to the development of novel therapeutic drugs for PTSD.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date March 2019
Est. primary completion date March 2019
Accepts healthy volunteers No
Gender All
Age group 13 Years to 18 Years
Eligibility [Inclusion Criteria]

1. Diagnosis of PTSD based on DSM-IV-TR criteria.

2. Score of 25 or higher on the IES-R.

3. currently is an outpatient at Chiba University Hospital Department of Psychiatry or Child Psychiatry .

4. currently receiving no medications for PTSD treatment with any of the following medications : Antidepressants (SSRI ; Fluvoxamine, Paroxetine, Sertraline, Escitalopram, SNRI ; Milnacipran, Duloxetine, NaSSa; Mirtazapine), Mood stabilizers (Lithium, Sodium Valproate, Carbamazepine, Lamotrigine), Atypical antipsychotics (Risperidone, Olanzapine, Quetiapine, Perospirone, Aripiprazole, Blonanserin, Paliperidone) .

5. Ages 13 - 18, male or female

6. be stable on any medications for PTSD treatment they may be taking for the previous 4 weeks prior to enrollment in this study.

7. Provision of written informed consent by patients and parents or guardian.

8. must be able to swallow powdered medicine.

[Exclusion Criteria]

1. History of allergic reaction or hypersensitivity to Ifenprodil Tartrate.

2. Patients who have not stopped bleeding after intracranial hemorrhage.

3. Patients who have not been informed of having the disease at the time of informed consent.

4. Diagnosis of any of the following diseases based on the DSM-IV-TR criteria. Mental Retardation, Pervasive Developmental Disorders, Attention-Deficit / Hyperactivity Disorder, Schizophrenia and Other Psychotic Disorders, Delirium, Dementia, and Amnestic and Other Cognitive Disorders, Substance-Related Disorders (except Caffeine-Related Disorders, Nicotine-Related Disorders) .

5. Somatic disorder which requires severe body management or severe meal management.

6. receiving treatment, with antidepressants, mood stabilizers, and atypical antipsychotics other than those of the inclusion criteria #4, within 4 weeks prior to enrollment in this study.

7. receiving treatment with the following N-methyl-D-aspartate (NMDA) receptor antagonists: Ketamine hydrochloride, Amantadine hydrochloride, Memantine hydrochloride, dextromethorphan, Methadone) within 4 weeks prior to enrollment in this study.

8. pregnant or nursing, or intending to become pregnant or to start breastfeeding during the study.

9. participating in another clinical trial within 3 months prior to enrollment into this study. (except for observation study without intervention).

10. planning change of treatment because of unstable neurological manifestations or somatic symptoms.

11. History of suicidal ideation within the past year.

12. Other clinically significant reasons for exclusion by investigators.

Study Design


Intervention

Drug:
Ifenprodil Tartrate

Placebo


Locations

Country Name City State
Japan Department of Psychiatry, Chiba University School of Medicine Chiba, Chuo-ku, Japan 260-8670 Chiba Chuo-ku

Sponsors (1)

Lead Sponsor Collaborator
Chiba University

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Other Children's Depression Rating Scale-Revised : CDRS-R The CDRS-R is a brief rating scale based on a semi-structured interview with the child (or an adult informant who knows the child well). Designed for 6- to 12-year-olds, and successfully used with adolescents, it can be administered in just 15 to 20 minutes and easily scored in a few minutes more. The interviewer rates 17 symptom areas (including those that serve as DSM-IV criteria for a diagnosis of depression) Changes from baseline in CDRS-R at 4-weeks
Other Depression Self-Rating Scale for Children Japanese Version: DSRS-C-J DSRS-C-J is easy to use and has a predictive value comparable with that of a psychiatric global rating of depressed appearance and history of depression obtained at interview. There was confirmation that the DSRS-C-J can tap an internal dimension of depression and that children are able to evaluate their feeling states. Changes from baseline in DSRS-C-J at 4-weeks
Other Clinical Global Impressions-Post Traumatic Stress Disorder-Improvement : CGI-PTSD-I The Clinical Global Impression rating scales are commonly used measures of symptom severity, treatment response and the efficacy of treatments in treatment studies of patients with mental disorders (Guy, W., 1976).
The Clinical Global Impression - PTSD - Improvement scale (CGI-PTSD-I) is a 7 point scale that requires the clinician to assess how much the PTSD has improved or worsened relative to a baseline state at the beginning of the intervention. and rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.
Changes from baseline in CGI-PTSD-I at 4-weeks
Other Clinical Global Impressions-Post Traumatic Stress Disorder-Severity : CGI-PTSD-S The Clinical Global Impression rating scales are commonly used measures of symptom severity, treatment response and the efficacy of treatments in treatment studies of patients with mental disorders (Guy, W., 1976).
The Clinical Global Impression -PTSD - Severity scale (CGI-PTSD-S) is a 7-point scale that requires the clinician to rate the severity of the PTSD at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.
Changes from baseline in CGI-PTSD-S at 4-weeks
Primary The Impact of Event Scale-Revised Japanese Version : IES-R-J Evidence includes retest reliability and internal consistency of the IES-R-J. Posttraumatic stress disorder (PTSD) and partial PTSD cases indicated significantly higher scores than non-PTSD cases. The IES-R-J can be a useful self-rating diagnostic instrument particularly for survivors with PTSD symptoms as a clinical concern (PTSD + partial PTSD) by using a 24/25 cutoff in total score. The IES-R-J can be used as a validated instrument in future international comparative research. Changes from baseline in IES-R-J at 4-weeks
Secondary Trauma Symptom Checklist for Children Japanese Version : TSCC-J The TSCC allows you to measure posttraumatic stress and related psychological symptomatology in children ages 8-16 years who have experienced traumatic events, such as physical or sexual abuse, major loss, or natural disasters, or who have been a witness to violence.
The 54-item TSCC includes two validity scales (Underresponse and Hyperresponse), six clinical scales (Anxiety, Depression, Anger, Posttraumatic Stress, Dissociation, and Sexual Concerns), and eight critical items. Profile Forms allow for conversion of raw scores to age- and sex-appropriate T scores and enable you to graph the results.
The TSCC-A, an alternate 44-item version of the measure, makes no reference to sexual issues.
Changes from baseline in TSCC-J at 4-weeks
See also
  Status Clinical Trial Phase
Terminated NCT00611871 - The Use of Propranolol to Block Memory Reconsolidation in PTSD Phase 2
Completed NCT02057081 - Multifamily Group to Reduce Marital Conflict and Disability in Veterans With mTBI N/A
Completed NCT03684473 - An Online CBT, Mindfulness Meditation & Yoga (CBT-MY) Intervention for Posttraumatic Stress Disorder N/A
Active, not recruiting NCT00965809 - Add on Study on Δ9-THC Treatment for Posttraumatic Stress Disorders (PTSD) Phase 4
Unknown status NCT01033708 - A Randomized Control Trial of Narrative Exposure Therapy Versus Treatment as Usual in the Therapy of Borderline Personality Disorder N/A
Completed NCT02774642 - Integrated CBT-I and PE on Sleep and PTSD Outcomes (Impact Study) N/A
Completed NCT01049516 - Prolonged Exposure for Post Traumatic Stress Disorder (PTSD) Among Operation Iraqi Freedom/Operation Enduring Freedom (OIF/OEF) Personnel N/A
Completed NCT00105885 - Telephone Care as a Substitute for Routine Psychiatric Medication N/A
Completed NCT02556645 - A Comparison of Web-Prolonged Exposure (Web-PE) and Present-Centered Therapy (PCT) for PTSD Among Active-Duty Military Personnel N/A
Recruiting NCT01743664 - The Efficacy of EMDR in Patients With PTSD in Multiple Sclerosis Phase 3
Completed NCT01158001 - Telemedicine for Improved Delivery of Psychosocial Treatments for Post Traumatic Stress Disorder N/A
Completed NCT03997344 - Veterans Nature Therapy (Vet Hike) N/A
Completed NCT01605253 - Eszopiclone for the Treatment of Posttraumatic Stress Disorder Phase 4
Not yet recruiting NCT02384369 - Trial of Oral SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder Phase 2
Enrolling by invitation NCT02757339 - Evaluating the Neurobiological Basis of Traumatic Dissociation in Women With Histories of Abuse and Neglect
Active, not recruiting NCT01157416 - Effect of D-cycloserine on Treatment of Posttraumatic Stress Disorder (PTSD) in Youth Phase 2
Completed NCT01208844 - Study of Physical Health for Women With Posttraumatic Stress or Depression N/A
Not yet recruiting NCT01914861 - Cortisol Diurnal Variation and the Risk for Developing Post Traumatic Stress Disorder N/A
Unknown status NCT01644851 - Cognitive Training for Post Traumatic Stress Disorder: Effects on Cognitive, Emotional, and Brain Function N/A
Recruiting NCT01947725 - Behavioral Activation for Smoking Cessation in Veterans With PTSD N/A